Human Stem Cells Institute PJSC announced reviewed consolidated interim results for the first nine months of 2017. For the period, the company reported revenue of RUB 352,284,000 against RUB 285,234,000 a year ago. OIBDA was negative at RUB 32,375,000 against RUB 85,970,000 a year ago. Operating loss was RUB 52,040,000 against RUB 104,783,000 a year ago. Net loss was RUB 31,056,000 against RUB 118,753,000 a year ago. The company's consolidated revenue for nine months 2017 amounted to RUB 352.284 million, a year-on-year increase of 23.5% as a result of increase in revenues from all the company's products and services in the market. The large portion of the consolidated revenue 47.3% was generated by HSCI PJSC as well as its subsidiaries, IMCB LLC and Cryonix JSC, from cord blood stem cell isolation, cryopreservation and personal storage service the business HSCI started its history in 2003 from. The second large revenue generator was Genetico services (genetic testing and counselling, reproductive cell bank /Reprobank /) with the share in the consolidated revenue of 40.0%. SPRS-therapy service provision accounted for 7.4%, the sales of Neovasculgen for 5.2%, other revenues for 0.1% of the consolidated revenue in the reporting period. The total (summarized) revenue generated by Genetico,SPRS-therapy and Neovasculgen increased by 45.0% year on year - from RUB 127.970 million in nine months 2016 to RUB 185.561 million in nine months 2017, and the share of the sum of these revenues in total revenue increased from 45% to 53%. Neovasculgen the first-in-class gene-therapy drug for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI).